Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Costimulation blockade with belatacept in renal transplantation.
Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B; Belatacept Study Group. Vincenti F, et al. N Engl J Med. 2005 Aug 25;353(8):770-81. doi: 10.1056/NEJMoa050085. N Engl J Med. 2005. PMID: 16120857 Clinical Trial.
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.
Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kvien TK, Williams S, Hagerty D, Cravets MW, Shaw T. Keystone E, et al. Ann Rheum Dis. 2009 Feb;68(2):216-21. doi: 10.1136/ard.2007.085787. Epub 2008 Apr 3. Ann Rheum Dis. 2009. PMID: 18388156 Clinical Trial.
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Genovese MC, et al. Among authors: hagerty dt. N Engl J Med. 2005 Sep 15;353(11):1114-23. doi: 10.1056/NEJMoa050524. N Engl J Med. 2005. PMID: 16162882 Free article. Clinical Trial.
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
Frenette CT, Morelli G, Shiffman ML, Frederick RT, Rubin RA, Fallon MB, Cheng JT, Cave M, Khaderi SA, Massoud O, Pyrsopoulos N, Park JS, Robinson JM, Yamashita M, Spada AP, Chan JL, Hagerty DT. Frenette CT, et al. Among authors: hagerty dt. Clin Gastroenterol Hepatol. 2019 Mar;17(4):774-783.e4. doi: 10.1016/j.cgh.2018.06.012. Epub 2018 Jun 18. Clin Gastroenterol Hepatol. 2019. PMID: 29913280 Free article. Clinical Trial.
Reply.
Hagerty D, Garcia-Tsao G, Bosch J. Hagerty D, et al. Hepatology. 2019 Sep;70(3):1079-1080. doi: 10.1002/hep.30681. Hepatology. 2019. PMID: 31034095 No abstract available.
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Shiffman M, Freilich B, Vuppalanchi R, Watt K, Chan JL, Spada A, Hagerty DT, Schiff E. Shiffman M, et al. Among authors: hagerty dt. Aliment Pharmacol Ther. 2019 Jan;49(1):64-73. doi: 10.1111/apt.15030. Epub 2018 Nov 14. Aliment Pharmacol Ther. 2019. PMID: 30430605 Free PMC article. Clinical Trial.
A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis.
Mehta G, Rousell S, Burgess G, Morris M, Wright G, McPherson S, Frenette C, Cave M, Hagerty DT, Spada A, Jalan R. Mehta G, et al. Among authors: hagerty dt. J Clin Exp Hepatol. 2018 Sep;8(3):224-234. doi: 10.1016/j.jceh.2017.11.006. Epub 2017 Nov 22. J Clin Exp Hepatol. 2018. PMID: 30302038 Free PMC article.
20 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page